<scp>PTX3</scp> mediates the infiltration, migration, and inflammation‐resolving‐polarization of macrophages in glioblastoma

Zhang, Hao; Wang, Yifan; Zhao, Yihan; Liu, Tao; Wang, Zeyu; Zhang, Nan; Dai, Ziyu; Wu, Wantao; Cao, Hui; Feng, Shi Ting; Zhang, Liyang; Cheng, Quan; Zhi-xiong, Liu

doi:10.1111/cns.13913

Cited by 21 publications

(26 citation statements)

References 63 publications

(119 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased synthesis of inflammatory biomarkers and activation of chemokine receptors (mediated through IL-6, IL-8, CX3CL1), leukocyte and stromal cells recruitment, induction of reactive oxidative species, hypoxia, and necrosis have been also identified in glioblastomas—highly aggressive astrocytic tumors [ 45 , 63 ]. Glioma represents one of the most common and lethal tumors in middle-aged and elderly individuals with a poor prognosis due to rapid cellular infiltration and invasiveness [ 64 , 65 ]. Unfortunately, tumor recurrence appears despite tumor resection, intensive healthcare, and treatment [ 63 , 65 ].…”

Section: Glioblastoma and Meningiomamentioning

confidence: 99%

“…Toll-like receptors (TLR) activation and transcription of NF-ƙB (emerged through prolyl-isomerase Pin1) also play an essential role in the inflammatory process within glioblastomas as cellular proliferation, migration, and apoptosis are further regulated [ 45 , 66 ]. Nevertheless, PTX-3 expression in gliomas is positively correlated with monocytes, fibroblasts, endothelial, and T cell levels [ 64 ]. Complement activation along with angiogenesis have also been noted in glioblastoma through PTX-3 modulation, similar to prostate and breast carcinomas [ 45 ].…”

Section: Glioblastoma and Meningiomamentioning

confidence: 99%

Section: Glioblastoma and Meningiomamentioning

confidence: 99%

“…However, PTX-3 was negatively correlated with IgG and B cell activation in the research conducted by Zhang et al, demonstrating inhibition of both immune and anti-tumor responses during cellular proliferation [ 64 ]. On the other hand, PTX-3 acts like a double-edge sword even in case of glioblastomas, as it promotes CD80 activation and Th1 differentiation [ 64 ]. Increased levels of regulatory T cells concomitant with reduced NK cells levels appear in patients receiving standard treatment (temozolomide and radiotherapy) after tumor resection [ 65 , 67 , 68 ].…”

Section: Glioblastoma and Meningiomamentioning

confidence: 99%

“…Consequently, the roles of PTX-3 in cancer depend on the type of the tumor and microenvironment, as different signaling pathways are regulated through PTX-3 [ 64 , 69 ]. Various mechanisms are similar, as for example, Zhang et al found that RELB (a critical regulon) could facilitate cellular proliferation and angiogenesis in both prostate cancer and gliomas and could also increase PD-L1 in prostate tumors [ 64 , 70 ].…”

Section: Glioblastoma and Meningiomamentioning

confidence: 99%

See 4 more Smart Citations

Insights into the Relationship between Pentraxin-3 and Cancer

Bogdan

Meca

Turcu-Știolică

et al. 2022

IJMS

View full text Add to dashboard Cite

Although cancer can be cured if detected early and treated effectively, it is still a leading cause of death worldwide. Tumor development can be limited by an appropiate immune response, but it can be promoted by chronic extensive inflammation through metabolic dysregulation and angiogenesis. In the past decade, numerous efforts have been made in order to identify novel candidates with predictive values in cancer diagnostics. In line with this, researchers have investigated the involvement of pentraxin-3 (PTX-3) in cellular proliferation and immune escape in various types of cancers, although it has not been clearly elucidated. PTX-3 is a member of the long pentraxin subfamily which plays an important role in regulating inflammation, innate immunity response, angiogenesis, and tissue remodeling. Increased synthesis of inflammatory biomarkers and activation of different cellular mechanisms can induce PTX-3 expression in various types of cells (neutrophils, monocytes, lymphocytes, myeloid dendritic cells, fibroblasts, and epithelial cells). PTX-3 has both pro- and anti-tumor functions, thus dual functions in oncogenesis. This review elucidates the potential usefulness of PTX-3 as a serum biomarker in cancer. While future investigations are needed, PTX-3 is emerging as a promising tool for cancer’s diagnosis and prognosis, and also treatment monitoring.

show abstract

Section: Glioblastoma and Meningiomamentioning

confidence: 99%

Section: Glioblastoma and Meningiomamentioning

confidence: 99%

Section: Glioblastoma and Meningiomamentioning

confidence: 99%

Section: Glioblastoma and Meningiomamentioning

confidence: 99%

Section: Glioblastoma and Meningiomamentioning

confidence: 99%

See 3 more Smart Citations

Insights into the Relationship between Pentraxin-3 and Cancer

Bogdan

Meca

Turcu-Știolică

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

Anoikis‐related signature in liver hepatocellular carcinoma defines the YBX1/SPP1 axis by machine learning strategies and valid experiments

She

Zhao

et al. 2023

The Journal of Gene Medicine

View full text Add to dashboard Cite

BackgroundLiver hepatocellular carcinoma (LIHC) remains a malignant malignancy with a low cure rate. Anoikis is a newly recognized cancer hallmark. However, an Anoikis‐related model has not been clarified in LIHC.MethodsThe Anoikis‐related score in the present study was created using Survival Random Forest and least absolute shrinkage and selection operator (LASSO) machine learning algorithms. Anoikis‐related scores with respect to mutation analysis, immunological analysis, function annotation, and medication prediction were all thoroughly investigated.ResultsThe Anoikis‐related score accurately predicted the patients' immunological activity, altered genes, and medication sensitivity. SPP1 immunological analysis, function annotation, medication prediction, and immunotherapy prediction were systematically investigated. SPP1 may effectively predict the outcomes of immunotherapy. SPP1 was revealed to be a mediator of LIHC cell proliferation and migration. A putative axis in LIHC was YBX1/SPP1.ConclusionsClinical care and the treatment plan for patients with LIHC were anticipated to benefit significantly from the established Anoikis‐related score.

show abstract

Exploring the impact of ITGB2 on glioma progression and treatment: Insights from non‐apoptotic cell death and immunotherapy

Zhuang,

Miao,

Liu

et al. 2024

Environmental Toxicology

View full text Add to dashboard Cite

In the realm of glioma treatment, our groundbreaking research has uncovered the pivotal role of Integrin Beta 2 (ITGB2) in non‐apoptotic cell death and its profound implications for immunotherapy efficacy. Gliomas, known for their aggressive and infiltrative nature, demand innovative therapeutic strategies for improved patient outcomes. Our study bridges a critical gap by examining the interplay between non‐apoptotic cell death and immunotherapy response in gliomas. Through comprehensive analysis of ten diverse glioma datasets, we developed a unique death enrichment score and identified ITGB2 as a significant risk marker. This study demonstrates that ITGB2 can predict immune activity, mutation characteristics, and drug response in glioma patients. We reveal that ITGB2 not only mediates glioma proliferation and migration but also crucially influences immunotherapy responses by modulating the interaction between gliomas and macrophages by single‐cell sequencing analysis (iTalk and ICELLNET). Employing a variety of molecular and cellular methodologies, including in vitro models, our findings highlight ITGB2 as a potent marker in glioma biology, particularly impacting macrophage migration and polarization. We present compelling evidence of ITGB2's dual role in regulating tumor cell behavior and shaping the immune landscape, thereby influencing therapeutic outcomes. The study underlines the potential of ITGB2‐targeted strategies in enhancing the efficacy of immunotherapy and opens new avenues for personalized treatment approaches in glioma management. In conclusion, this research marks a significant stride in understanding glioma pathology and therapy, positioning ITGB2 as a key biomarker and a promising target in the quest for effective glioma treatments.

show abstract

PTX3 mediates the infiltration, migration, and inflammation‐resolving‐polarization of macrophages in glioblastoma

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 21 publications

References 63 publications

Insights into the Relationship between Pentraxin-3 and Cancer

Insights into the Relationship between Pentraxin-3 and Cancer

Anoikis‐related signature in liver hepatocellular carcinoma defines the YBX1/SPP1 axis by machine learning strategies and valid experiments

Exploring the impact of ITGB2 on glioma progression and treatment: Insights from non‐apoptotic cell death and immunotherapy

Contact Info

Product

Resources

About